Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
ESBATech
company
About
ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.
- 51 - 100
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- Fr14.50M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 1998
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
Fr14.50M
ESBATech has raised a total of
Fr14.50M
in funding over 2 rounds. Their latest funding was raised on
May 14, 2002 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 14, 2002 | Series A | Fr14.50M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
ESBATech is funded by 1 investors.
LODH Immunology Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
